Connection

Contact Us
If you have any questions or feedback please contact us.

Search Results to Robert Charles Doebele

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Doebele, Robert

One or more keywords matched the following items that are connected to Doebele, Robert

Item Type	Name
Academic Article	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Academic Article	Oncogenic fusions involving exon 19 of ALK.
Academic Article	Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
Academic Article	Genetic testing for lung cancer: reflex versus clinical selection.
Academic Article	Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.
Academic Article	Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
Academic Article	Targeting ALK, ROS1, and BRAF kinases.
Academic Article	Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
Academic Article	Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
Concept	Oncogene Fusion
Concept	Oncogene Proteins, Fusion
Concept	Oncogenes
Concept	Proto-Oncogene Proteins B-raf
Concept	Oncogene Proteins
Concept	Proto-Oncogene Proteins p21(ras)
Concept	Proto-Oncogene Proteins c-ret
Concept	Proto-Oncogene Proteins c-mdm2
Concept	Proto-Oncogene Proteins c-met
Concept	Proto-Oncogene Proteins
Concept	Proto-Oncogene Proteins c-kit
Academic Article	Molecular pathways: ROS1 fusion proteins in cancer.
Academic Article	Targeted therapies: Time to shift the burden of proof for oncogene-positive cancer?
Academic Article	Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
Academic Article	Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
Academic Article	ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
Academic Article	Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.
Academic Article	The democratization of the oncogene.
Academic Article	The minority report: targeting the rare oncogenes in NSCLC.
Academic Article	Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Academic Article	TRKing down an old oncogene in a new era of targeted therapy.
Academic Article	Activation of RAS family members confers resistance to ROS1 targeting drugs.
Academic Article	Rearranging Detection of Gene Rearrangements.
Academic Article	RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.
Academic Article	An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Academic Article	Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status.
Academic Article	A framework for understanding and targeting residual disease in oncogene-driven solid cancers.
Academic Article	An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
Academic Article	Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
Academic Article	Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance.
Academic Article	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Grant	The role of EGFR as a mechanism of therapeutic resistance in gene fusion positive lung cancer.
Academic Article	EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.
Academic Article	Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.
Academic Article	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Academic Article	Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.
Academic Article	ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms.
Academic Article	Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.
Academic Article	Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Academic Article	Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.
Academic Article	Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
Academic Article	Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples.
Academic Article	The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Academic Article	Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Academic Article	First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance.
Academic Article	A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
Academic Article	ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events.
Academic Article	Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.
Academic Article	Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
Academic Article	Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.
Academic Article	Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.
Academic Article	Acquired Resistance Is Oncogene and Drug Agnostic.
Academic Article	Targeted therapies for ROS1-rearranged non-small cell lung cancer.
Academic Article	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Academic Article	Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma.
Academic Article	Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.
Academic Article	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Academic Article	Novel Human-Derived RET Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling.
Academic Article	Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.
Academic Article	Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.
Academic Article	Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Academic Article	Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC.
Academic Article	Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib.
Academic Article	GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.
Academic Article	Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma.
Academic Article	Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
Academic Article	MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC.
Academic Article	A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.
Academic Article	ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression.
Academic Article	A Rapid, Functional sgRNA Screening Method for Generating Murine RET and NTRK1 Fusion Oncogenes.

Search Criteria

Oncogenes